Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

DURECT Corporation (DRRX): First Eagle Raises Its Stake; See Investor’s Other Healthcare Picks

Page 1 of 2

As a new filing with the Securities and Exchange Commission showed, Jean-Marie Eveillard‘s First Eagle Investment Management has increased its stake in DURECT Corporation (NASDAQ:DRRX) to 13.13 million shares. The passive stake that accounts for 11.54% of the company’s common stock was increased from 10.71 million shares the fund held at the end of 2014.

DURECT Corporation

DURECT Corporation (NASDAQ:DRRX) is a nano-cap pharmaceutical company that develops specialty drugs based on its proprietary drug delivery technology platform. For the last year, the company posted a revenue growth to $19.4 million from $15.3 million a year earlier and a net loss of $22.1 million, wider than $21.5 million in 2013. On the back of the results, the company’s stock surged and is currently up by over 110% since the beginning of the year, although over the last 52 weeks it gained only 10%, which is significantly below the specialy & generic drug manufacturers’ industry return of 41%.

First Eagle initiated a stake in DURECT Corporation (NASDAQ:DRRX) during the first quarter of 2012 and initially held 1.94 million shares. However, as the stock almost doubled since the end of March 2012, the fund significantly increased its exposure to the company. Another investor that is bullish on Durect Corporation is healthcare-focused Broadfin Capital, led by Kevin Kotler, which holds 4.40 million shares as of the end of 2014. However, due to the small size of the company, in the equity portfolios of all funds that we track the stake in DURECT Corporation (NASDAQ:DRRX) represents a very small percentage of total value.

First Eagle has a very large equity portfolio that is valued at more than $41 billion as of the end of 2014 and contains over 350 positions. The investor prefers to hold stakes in Technology, Materials, Finance, Energy, and Consumer Discretionary stocks, which amass around 80% of its equity portfolio,  but it also invests smaller amounts in other sectors, such as Healthcare, about which we are going to talk next. Therefore, according to its last 13F filing, First Eagle held around 7% of its equity portfolio in Healthcare stocks, the majority of which are large-cap companies. Three largest healthcare positions held by the fund as of the end of last year are represented by Actavis plc (NYSE:ACT), Valeant Pharmaceuticals Intl Inc (NYSE:VRX), and Johnson & Johnson (NYSE:JNJ).

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!